Background: Adjuvant tegafur/uracil (UFT) chemotherapy is recommended for patients with completely resected Stage I non-small cell lung cancer (NSCLC) in Japan. A Phase III trial, the Japan Clinical Oncology Group (JCOG) 0707, comparing the survival benefit of UFT and S-1 (tegafur/ gimeracil/oteracil) for this population is being conducted. However, the selection of patients in the randomized clinical trial (RCT) may not represent the real-world population. The present study aimed to investigate the pattern of care for patients receiving adjuvant chemotherapy for completely resected NSCLC. Methods: Patients with completely resected pathological Stage I (T1 > 2 cm and T2 in 6th TNM edition) NSCLC eligible for the JCOG0707 trial but excluded from it during the enrollment period (2008-13) were eligible for this study. Physicians from institutions that participated in the JCOG0707 retrospectively assessed the medical records of each patient. Results: This study enrolled 5006 patients, 85% of those initially considered for participation in the JCOG0707 trial (5006 of 5923 patients). Among them, 2389 were ineligible for the trial and 2617 had not been enrolled despite being eligible. The most frequent reason for non-enrollment despite eligibility was the decline in patients' participation, and the major reasons for trial ineligibility were concomitant malignancy and comorbidities. Of all the patients enrolled in our study, 1659 received adjuvant chemotherapy, mainly UFT.
Introduction
Non-small cell lung cancer (NSCLC) accounts for~85% of all lung cancers. Surgery is still considered the principal treatment option in patients with early stage NSCLC, but even these patients have high risk of recurrence and death from lung cancer (1) . The Japanese nationwide lung cancer registry report analyzed the clinical outcomes of 11 663 patients who underwent surgery in 2004 and showed that the 5-year overall survival (OS) rate was 85.9% for pathological Stage IA and 69.3% for Stage IB (6th TNM edition) (2) . According to this report, the OS for the entire pathological Stage IA group appeared excellent, but the 5-year OS rate for pathological Stage IA group with a tumor size > 2 cm (2.1-3.0 cm) at 69% was unsatisfactory, as was the OS rate for the pathological Stage IB group (2) .
The cisplatin-based adjuvant chemotherapy has become a global standard of care for patients with completely resected early stage NSCLC, particularly for those with Stages II to III disease (3) . In 2004, a Japanese Phase III trial showed that adjuvant chemotherapy with oral tegafur/uracil (UFT) significantly improved the OS in comparison to surgery alone for patients with completely resected Stage I lung adenocarcinoma, particularly for those with Stage IB disease (6th TNM edition) (4) . Furthermore, a meta-analysis of 2003 patients with completely resected NSCLCs from six randomized trials in Japan showed the efficacy of adjuvant UFT, regardless of the histological type, and even patients with Stage IA disease with T1 > 2 cm displayed a 5-year survival benefit (6%) (5, 6) . Based on these results, in Japan, adjuvant UFT is generally recommended for patients with completely resected Stage I (T1 > 2 cm and T2 in 6th TNM edition) NSCLC. This strategy has not been evaluated in Caucasian patients.
S-1 is a second-generation oral anticancer agent based on UFT, which has a dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine. S-1 comprises tegafur (a 5-FU Prodrug), 5-chloro-2, 4-dihydroxypyridine (an inhibitor of DPD), and potassium oxonate (an inhibitor of phosphoribosyl transferase) in a molar ratio of 1:0.4:1 and has been shown to induce a comparable response to that of other single agents for metastatic NSCLC (7, 8) . The Japan Clinical Oncology Group (JCOG) initiated a randomized Phase III trial (JCOG0707, the UMIN Clinical Trials Registry as UMIN000001494) comparing the survival benefit of UFT and S-1 for patients with completely resected pathological Stage I (T1 > 2 cm and T2 in 6th TNM edition) NSCLC (9) . The enrollment for 963 patients occurred between November 2008 and December 2013; the JCOG0707 trial will continue until the completion of the survival follow-up period, and its main results are expected to be available in 2019 (9) .
However, there is a growing concern that the patients in the randomized clinical trials (RCTs) were highly selected and did not represent the real-world population. Thus, the RCT results will probably not apply to the general patient population (10) . Realworld studies, such as those based on patient registries and observational cohort studies, are required to properly reproduce the results of RCTs into clinical practice.
Herein, a multicenter observational cohort study was conducted for the patients excluded from the JCOG0707 during the study enrollment period. The main purpose of this study was to investigate the reasons for the non-enrollment of patients with completely resected early stage NSCLC into the RCT of adjuvant chemotherapy in Japan. The pattern of care in adjuvant therapy was also assessed in this real-world population to provide external validity to the future results of the JCOG0707 trial.
Patients and methods

Study design
This study was an observational cohort multicenter study in Japan. Patients who had completely resected pathological Stage I (T1 > 2 cm and T2 in 6th TNM edition) NSCLC, as confirmed with lobectomy/pneumonectomy and nodal dissection/sampling, i.e., who belonged to the target population of the JCOG0707 trial, but who were excluded from it during that study's enrollment period were eligible to participate in this study. The enrollment period of the JCOG0707 trial occurred between November 2008 and December 2013. Researchers from institutions participating in the JCOG0707 trial recorded data from the medical records of each patient in this study, which was designed as published (11) .
The study was conducted according to the tenets of the Declaration of Helsinki and approved by the institutional review board of each participating institute as well as the ethical committee at the Public Health Research Foundation. The opt-out method, which provides opportunities to prevent patient rejection through information disclosure via posting and publication, was applied to obtain informed consents. This policy is based on the Ethical Guidelines for Epidemiological Research in Japan. However, each institution responded by following the instructions from their respective institutional review boards and obtained informed consents from individual patients when those boards deemed it necessary. Clinical registration number is UMIN000015732.
Outcome
The primary outcome was the proportion of excluded patients from the JCOG0707 trial and the reasons for exclusion. The proportions of excluded patients among institutions were also compared, and patients were classified into one of six categories according to the reasons for exclusion from the JCOG0707 trial: (1) ineligible for JCOG0707, (2) decline in patients' participation, (3) temporary suspension of JCOG0707 accrual, (4) attending physician failed to provide information about the trial, (5) physicians' direction and (6) others. Secondary outcomes were to determine patient characteristics, tumor profiles, and postoperative treatment status of the patients excluded from the JCOG0707 trial. Patients were divided into two groups according to the postoperative treatment status: (1) patients who received postoperative adjuvant therapy and (2) patients who did not receive postoperative treatment.
Statistical analysis
A univariate analysis was performed to find associations between clinical and pathological factors and the postoperative treatment status. Furthermore, multivariate analyses were performed using logistic regression models. Missing data were not imputed. All comparisons were performed using the chi-square test. P values <0.05 were considered statistically significant. All data analyses were performed with the SAS/STAT software (version 9.3; SAS Institute, Cary, NC, USA).
Results
Of the 48 institutions that participated in the JCOG0707 trial, 34 (enrolling 917 (95%) of all 963 patients registered in the JCOG0707) cooperated in this study. A total of 5006 patients with completely resected pathological Stage I (T1 > 2 cm and T2 in 6th TNM edition) NSCLC were enrolled in this study after being excluded from the JCOG0707 trial. Figure 1 shows a flow chart of this study. The proportion of excluded patients from the JCOG0707 trial was 85% (5006 of 5923 patients) included patients from various institutions (54-96%) (Fig. 2) . Patient characteristics are listed in Table 1 , with the characteristics of patients who had registered into the JCOG0707 trial (12) . Their median age was 69 (range, 20-93) years and less than half of them were women. The majority of patients had adenocarcinoma histology (75%), and the tumor staging classification included 2536 T1 (>2 cm) and 2470 T2 tumors.
Among the 5006 patients excluded from the JCOG0707 trial, 2389 (48%) were ineligible for the trial and 2617 (52%) had not been enrolled despite their eligibility. The most frequent reason for non-enrollment despite eligibility was decline in patient's participation. The reasons for participation decline included the refusal of adjuvant chemotherapy and the request for standard therapy as UFT in half of the patients. The reasons for exclusion from the JCOG0707 trial are shown in Table 2 . Approximately one-third of the patients in our study (1659 or 33%) received adjuvant therapy with standard UFT (1550 or 93%) and with experimental S-1 (21 or 1%). Sixty-seven (4%) patients received platinum-based chemotherapy. In addition, of the 1550 patients who received UFT, 971 (63%) continued the treatment for at least 1 year. No difference was found in the proportion of patients who continued UFT for at least 1 year between those ineligible for the trial and those not enrolled despite being eligible (61% vs. 64%).
A univariate analysis was performed to identify factors associated with the non-use of adjuvant therapy (Table 3) . Of 2389 ineligible patients for the JCOG0707 trial, 78% received no adjuvant therapy and 57% of the 2617 non-enrolled patients despite eligibility received no adjuvant therapy (P < 0.001). Age, surgical procedure, lymph node dissection, histology, tumor size, pathological stage and JCOG0707 trial eligibility were all associated with the adjuvant therapy status. A multivariate analysis was performed based on the results of the univariate analysis ( Table 4 ). The results of the multivariate analysis showed that age, surgical procedure, lymph node dissection, histology, tumor size and JCOG0707 trial eligibility were the significant independent variables.
Discussion
In our study, only 15% of the patients with completely resected early stage NSCLC in Japan during the enrollment period were enrolled in the clinical JCOG0707 trial for adjuvant chemotherapy. Half of the patients excluded from the JCOG0707 were not enrolled despite having met the study eligibility criteria. One-third of the patients excluded from the JCOG0707 trial received adjuvant chemotherapy, and most of them with UFT, which is the standard therapy according to the Japan Lung Cancer Society guideline. Few patients received experimental therapies by the attending physicians. The reasons for the low enrollment rate in the JCOG0707 trial are discussed below.
The implementation of adjuvant chemotherapy for completely resected NSCLC is still low, 22-40% of patients in the clinical practice receive this therapy (13) (14) (15) . Although adjuvant chemotherapy improves survival in patients with completely resected NSCLC, it could be associated with severe toxicity or lethal adverse events. The adverse events of UFT are relative mild, but the treatment duration for at least 1 year is long and uncomfortable for patients. Therefore, attending physicians or patients may hesitate to use adjuvant chemotherapy after complete surgical resection. Moreover, Stage I NSCLC, such as lung adenocarcinoma, with predominant lepidic growth is known to have a favorable prognosis. For patients with such tumors, attending physicians may not recommend adjuvant chemotherapy. In addition, the latest TNM classification ( 8th edition) for lung cancer changed the definition of T factor simple size to invasive size (16) . Therefore, it is unclear which subpopulation of Stage I NSCLC is suitable for adjuvant chemotherapy according to the latest TNM classification.
The study eligibility criteria for RCTs are strict, and as a consequence, the study participants are often limited to highly selected populations. According to our results, the major reasons for ineligibility for the JCOG0707 trial were the presence of concomitant malignancy and comorbidities. NSCLC is generally associated with smoking, and thus many patients with NSCLC present concomitant malignancies and comorbidities, such as cardiovascular or lung disease, and tend to be ineligible for clinical trials. The safety and efficacy outcomes of eligible and ineligible patients for the SWOG leukemia trials were shown to be comparable in a recent report (17) . We suggest that the study eligibility criteria for RCTs should reflect the real-world population as much as possible without impacting the primary endpoint (such as the OS) (18, 19) . In RCTs for the patients with completely resected early stage NSCLC, the enrollment of those with concomitant malignancies and comorbidities without affecting survival should be allowed in the future. Subsets of patients with early mortality with the use of adjuvant chemotherapy for completely resected NSCLC have been reported (20) . According to this study, older age, higher comorbidity scores, and a more complicated postoperative course were all associated with an increased early mortality risk. A follow-up of our patients is currently being conducted to obtain survival data. Additional information including the early mortality rate will be obtained in our real-world population with completely resected early stage NSCLC in Japan. In the future, we will also be able to compare the survival data between the real-world population excluded from the JCOG0707 trial in our study and the data from the patients who participated in the JCOG0707 trial.
A major limitation of our study is that the reasons for exclusion from the JCOG0707 trial were retrospectively collected, and this is not the most reliable method to properly assess the reasoning of physicians and patients at the time of enrollment. RCTs for adjuvant chemotherapy for completely resected early stage NSCLC usually require more time than initially allotted, and the JCOG0707 trial actually required over 5 years to complete the planned patient accrual. However, observational cohort studies with real-world populations may occur at a much faster rate and complement the RCTs' evidence. We believe that our real-world data will be useful for interpreting the results of the JCOG0707 trial in clinical practice.
In conclusion, our results indicate that only 15% of the patients in the real-world population with completely resected early stage NSCLC in Japan were enrolled into the adjuvant chemotherapy JCOG0707 trial during its enrollment period and that one-third of those not enrolled received adjuvant chemotherapy during the normal treatment course. Most adjuvant chemotherapies used were the UFT standard therapy. Additionally, a second part of our study is being conducted to obtain and analyze the survival data in the realworld population of patients excluded from the JCOG0707 trial. We believe that our complete analysis, including the survival data, will be needed to externally validate the results of the JCOG0707 trial.
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